Table 1 Association between SOX1 expression and clinicopathologic characteristics
From: MiR-155-5p suppresses SOX1 to promote proliferation of cholangiocarcinoma via RAF/MEK/ERK pathway
Clinicopathologic characteristics | ||||
|---|---|---|---|---|
Clinical charactics | Numbers of patients | SOX1 | P value | |
Low expression | High expression | |||
Age (years) | 0.405 | |||
≤ 60 | 4 | 2 | 2 | |
> 60 | 5 | 4 | 1 | |
Gender | 0.405 | |||
Male | 5 | 4 | 1 | |
Female | 4 | 2 | 2 | |
Tumor size (cm) | 0.048 | |||
≤ 3 | 4 | 1 | 3 | |
> 3 | 5 | 5 | 0 | |
Lymph node metastasis | 0.226 | |||
Negative | 6 | 5 | 1 | |
Positive | 3 | 1 | 2 | |
TNM stage | 0.405 | |||
I and II | 5 | 4 | 1 | |
III and IV | 4 | 2 | 2 | |